DaVita HealthCare Partners Inc. (NYSE:DVA) has been given a $66.00 price target by equities researchers at SunTrust Banks Inc. in a research note issued to investors on Thursday. The brokerage currently has a a “hold” rating on the stock. SunTrust Banks Inc.’s price objective points to a potential upside of 5.33% from the company’s current price.

DVA has been the subject of several other research reports. JPMorgan Chase & Co. increased their target price on shares of DaVita HealthCare Partners from $74.00 to $75.00 and gave the company a “neutral” rating in a research note on Tuesday, August 9th. Raymond James Financial Inc. raised shares of DaVita HealthCare Partners from a “market perform” rating to an “outperform” rating and set a $75.00 price target for the company in a research report on Tuesday, September 20th. Zacks Investment Research lowered shares of DaVita HealthCare Partners from a “hold” rating to a “sell” rating in a research report on Wednesday, July 27th. Citigroup Inc. assumed coverage on shares of DaVita HealthCare Partners in a research report on Tuesday, September 6th. They issued a “neutral” rating and a $71.00 price target for the company. Finally, TheStreet lowered shares of DaVita HealthCare Partners from a “buy” rating to a “hold” rating in a research report on Monday, August 8th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $75.50.

Analyst Recommendations for DaVita HealthCare Partners (NYSE:DVA)

Shares of DaVita HealthCare Partners (NYSE:DVA) traded up 0.630% during mid-day trading on Thursday, reaching $63.055. The company had a trading volume of 850,969 shares. The company’s 50-day moving average price is $64.53 and its 200-day moving average price is $72.44. The company has a market capitalization of $13.05 billion, a PE ratio of 36.681 and a beta of 0.96. DaVita HealthCare Partners has a 52-week low of $61.36 and a 52-week high of $78.94.

DaVita HealthCare Partners (NYSE:DVA) last released its earnings results on Monday, August 8th. The company reported $1.01 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.98 by $0.03. DaVita HealthCare Partners had a net margin of 2.51% and a return on equity of 16.48%. The business earned $3.72 billion during the quarter, compared to analysts’ expectations of $3.67 billion. During the same quarter last year, the company earned $0.95 earnings per share. The firm’s revenue was up 8.2% on a year-over-year basis. On average, analysts forecast that DaVita HealthCare Partners will post $3.76 earnings per share for the current fiscal year.

In other news, COO Michael David Staffieri sold 20,262 shares of the stock in a transaction that occurred on Tuesday, August 9th. The shares were sold at an average price of $73.09, for a total transaction of $1,480,949.58. Following the sale, the chief operating officer now directly owns 52,279 shares of the company’s stock, valued at $3,821,072.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 2.10% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in DVA. Speece Thorson Capital Group Inc. boosted its stake in DaVita HealthCare Partners by 1.4% in the second quarter. Speece Thorson Capital Group Inc. now owns 181,101 shares of the company’s stock valued at $14,003,000 after buying an additional 2,560 shares during the period. Geode Capital Management LLC boosted its stake in DaVita HealthCare Partners by 1.0% in the first quarter. Geode Capital Management LLC now owns 1,417,807 shares of the company’s stock valued at $103,840,000 after buying an additional 13,776 shares during the period. State Board of Administration of Florida Retirement System boosted its stake in DaVita HealthCare Partners by 19.7% in the second quarter. State Board of Administration of Florida Retirement System now owns 277,939 shares of the company’s stock valued at $21,490,000 after buying an additional 45,749 shares during the period. Westpac Banking Corp boosted its stake in DaVita HealthCare Partners by 30.4% in the second quarter. Westpac Banking Corp now owns 9,485 shares of the company’s stock valued at $733,000 after buying an additional 2,213 shares during the period. Finally, Whittier Trust Co. boosted its stake in DaVita HealthCare Partners by 3.5% in the second quarter. Whittier Trust Co. now owns 46,414 shares of the company’s stock valued at $3,588,000 after buying an additional 1,548 shares during the period. 83.55% of the stock is currently owned by institutional investors and hedge funds.

DaVita HealthCare Partners Company Profile

DaVita HealthCare Partners Inc is a provider of kidney care services. The Company operates Kidney Care division and HealthCare Partners (HCP) division. Its segments include U.S. dialysis and related lab services, HCP and Other-Ancillary services and strategic initiatives. Its Kidney Care division is a provider of dialysis services in the United States, treating patients with chronic kidney failure and end stage renal disease (ESRD).

5 Day Chart for NYSE:DVA

Receive News & Stock Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related stocks with our FREE daily email newsletter.